"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States DNA Synthesis Market size was estimated at USD 1.82 billion in 2025 and is projected to reach USD 6.34 billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 13.3% from 2026 to 2035. Key trends include increasing adoption of synthetic biology, expanding gene and cell therapy programs, growing use of enzymatic DNA synthesis, AI-assisted sequence design, laboratory automation, cloud-enabled bioinformatics, precision medicine, molecular diagnostics, high-throughput DNA manufacturing, and increasing enterprise demand for scalable and high-fidelity genetic constructs.

United States DNA Synthesis Market Overview

The United States DNA Synthesis Market is emerging as a foundational component of the biotechnology ecosystem, supporting pharmaceutical research, synthetic biology, molecular diagnostics, agricultural biotechnology, precision medicine, and advanced therapeutic development. Increasing reliance on customized genetic constructs is encouraging pharmaceutical companies, biotechnology organizations, academic institutions, and contract research organizations to adopt commercial DNA synthesis solutions that reduce research timelines, improve experimental reproducibility, and support increasingly complex genomic applications.

Growing demand for scalable and high-quality DNA manufacturing is transforming procurement priorities across the biotechnology industry. Enterprise customers increasingly evaluate suppliers based on synthesis accuracy, sequence complexity, turnaround time, production scalability, quality assurance, regulatory compliance, intellectual property protection, and digital workflow integration. This shift is strengthening the position of providers capable of delivering high-fidelity DNA constructs alongside comprehensive bioinformatics, validation, and technical support services.

Technological advancement is further reshaping the industry through enzymatic DNA synthesis, artificial intelligence-assisted sequence optimization, robotic laboratory automation, cloud-based bioinformatics, and integrated laboratory management systems. These technologies improve manufacturing efficiency, increase production throughput, and support the development of longer and more complex genetic constructs. Pharmaceutical and biotechnology companies are increasingly seeking integrated providers capable of combining molecular engineering expertise with enterprise-grade manufacturing and computational infrastructure.

Gene and cell therapy, synthetic biology, precision medicine, and molecular diagnostics are creating additional commercial opportunities for DNA synthesis providers. As biotechnology development becomes increasingly data-driven and automated, demand is shifting toward suppliers that can provide scalable manufacturing, advanced computational design, quality validation, and end-to-end workflow integration. The US therefore remains a strategically important market for next-generation DNA manufacturing and genomic innovation.

DNA Synthesis Technology Investments Accelerate Next-Generation Biotechnology Development

2025–2026 — DNA synthesis providers continued strengthening manufacturing infrastructure, enzymatic synthesis platforms, laboratory automation, artificial intelligence-assisted sequence design, and digital bioinformatics capabilities to address increasing enterprise demand from pharmaceutical, biotechnology, gene therapy, synthetic biology, and research organizations.

Key Takeaways from the Report

Gene Synthesis Services contributed nearly 34.8% of market revenue, maintaining leadership across pharmaceutical research, synthetic biology, therapeutic development, and commercial biotechnology applications.
Enzymatic DNA Synthesis is projected to expand at a CAGR of around 18.2%, supported by improved synthesis accuracy, longer construct capabilities, environmental advantages, and scalable manufacturing potential.
AI-assisted sequence design and laboratory automation influenced over 43% of technology investments, accelerating DNA design, manufacturing efficiency, quality control, and workflow optimization.
Gene and cell therapy programs represented more than 36% of commercial DNA synthesis demand, reinforcing procurement activity for plasmid development, vector engineering, genome editing, and therapeutic construct optimization.
Drug Discovery & Development remains a leading application due to continuous demand for custom DNA constructs supporting target identification, therapeutic screening, biologic engineering, and translational research.
Pharmaceutical & Biotechnology Companies represent the leading end-user segment, supported by extensive research pipelines requiring high-quality synthetic DNA for therapeutic innovation, vaccine development, and genomic engineering.
Large-Scale Manufacturing is gaining momentum as gene therapies, industrial biotechnology, and synthetic biology applications increase enterprise requirements for standardized and high-volume DNA production.
Artificial intelligence, robotic automation, cloud-enabled bioinformatics, and integrated laboratory systems are creating new opportunities for DNA synthesis providers by improving scalability, traceability, production planning, and customer collaboration.

Top Players

Thermo Fisher Scientific Inc.
Integrated DNA Technologies (IDT)
GenScript Biotech Corporation
Twist Bioscience Corporation
Eurofins Scientific
Azenta Life Sciences
Synbio Technologies
OriGene Technologies, Inc.
LGC Biosearch Technologies
ATUM
Evonetix Ltd.
DNA Script
Elegen Corporation
Telesis Bio Inc.
Bio Basic Inc.

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest Announcement

May 2026 — Evonetix accelerated commercialization of semiconductor-based DNA synthesis technology, strengthening next-generation DNA manufacturing capabilities and supporting the industry’s transition toward advanced, scalable synthesis platforms.